Proposed Changes to Best Price and Market Dynamics

This analytical report examines the CMS's proposed changes to the Best Price definition under the Medicaid Drug Rebate Program. It explores potential impacts on drug pricing, Medicaid rebate liabilities, and market dynamics for stakeholders including manufacturers, payers, and providers. The report highlights implications for commercial payer rebates, channel discounts, and innovative arrangements, providing insights into how these changes could reshape the healthcare landscape.